Literature DB >> 21294766

A first national prevalence estimate of diagnosed and undiagnosed diabetes in France in 18- to 74-year-old individuals: the French Nutrition and Health Survey 2006/2007.

C Bonaldi1, M Vernay, C Roudier, B Salanave, A Oleko, A Malon, K Castetbon, A Fagot-Campagna.   

Abstract

AIMS: To estimate the nationwide prevalence of diagnosed and undiagnosed diabetes and pre-diabetes in adults residing in France.
METHODS: A probability sample of a non-institutionalized civilian population residing throughout the whole of continental France was recruited from February 2006 to March 2007 for the French Nutrition and Health Survey. All individuals aged between 18 and 74 years who agreed to participate in the survey were included; thus there were 3115 participants, 2102 of whom were undergoing biochemical assessments. The prevalence of diagnosed diabetes was estimated using self-reported diabetes history and the prevalence of undiagnosed diabetes was estimated using fasting plasma glucose ≥ 7.0 mmol/l or HbA(1c) ≥ 6.5% (≥ 48 mmol/mol).
RESULTS: The prevalence of diagnosed diabetes was 4.6%, 95% CI 3.6-5.7. The prevalence of undiagnosed diabetes according to standard fasting plasma glucose criteria was 1% (95% CI 0.6-1.7) and contributed to less than 20% of all cases of diabetes. This proportion decreased with age from 30% in 30- to 54-year-olds to 12% in 55- to 74-year-olds. Based on HbA(1c) criteria, the prevalence of undiagnosed diabetes was 0.8% (95% CI 0.4-1.6).
CONCLUSIONS: The prevalence of diagnosed diabetes in adults in France is comparable with recent estimates from Northern Europe. The percentage of total diabetes that is undiagnosed is low in France, which may be explained by a widely practised strategy of opportunist screening. During the past years, improvements in diabetes care and increased awareness may have contributed towards decreasing the prevalence of undiagnosed diabetes more widely in Europe, and studies should further monitor such improvements.
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Year:  2011        PMID: 21294766     DOI: 10.1111/j.1464-5491.2011.03250.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  17 in total

1.  Metabolic syndrome and socioeconomic status in France: The French Nutrition and Health Survey (ENNS, 2006-2007).

Authors:  M Vernay; B Salanave; C de Peretti; C Druet; A Malon; V Deschamps; S Hercberg; K Castetbon
Journal:  Int J Public Health       Date:  2013-09-03       Impact factor: 3.380

2.  Mutations and variants of ONECUT1 in diabetes.

Authors:  Anne Philippi; Sandra Heller; Ivan G Costa; Valérie Senée; Marc Nicolino; Cécile Julier; Alexander Kleger; Markus Breunig; Zhijian Li; Gino Kwon; Ronan Russell; Anett Illing; Qiong Lin; Meike Hohwieler; Anne Degavre; Pierre Zalloua; Stefan Liebau; Michael Schuster; Johannes Krumm; Xi Zhang; Ryan Geusz; Jacqueline R Benthuysen; Allen Wang; Joshua Chiou; Kyle Gaulton; Heike Neubauer; Eric Simon; Thomas Klein; Martin Wagner; Gopika Nair; Céline Besse; Claire Dandine-Roulland; Robert Olaso; Jean-François Deleuze; Bernhard Kuster; Matthias Hebrok; Thomas Seufferlein; Maike Sander; Bernhard O Boehm; Franz Oswald
Journal:  Nat Med       Date:  2021-10-18       Impact factor: 87.241

3.  Prevalence and comorbidity of diabetes mellitus among non-institutionalized older adults in Germany - results of the national telephone health interview survey 'German Health Update (GEDA)' 2009.

Authors:  Yong Du; Christin Heidemann; Antje Gößwald; Patrick Schmich; Christa Scheidt-Nave
Journal:  BMC Public Health       Date:  2013-02-23       Impact factor: 3.295

4.  Impact of diabetes on work cessation: data from the GAZEL cohort study.

Authors:  Eléonore Herquelot; Alice Guéguen; Sébastien Bonenfant; Rosemary Dray-Spira
Journal:  Diabetes Care       Date:  2011-05-11       Impact factor: 19.112

5.  Routine data sources challenge international diabetes Federation extrapolations of national diabetes prevalence in Switzerland.

Authors:  Matthias Bopp; Ueli Zellweger; David Faeh
Journal:  Diabetes Care       Date:  2011-09-16       Impact factor: 19.112

6.  Assessing the effect of treatment duration on the association between anti-diabetic medication and cancer risk.

Authors:  Anna But; Haining Wang; Satu Männistö; Eero Pukkala; Jari Haukka
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

7.  The prevalence and correlates of pre-diabetes in middle- to older-aged Irish adults using three diagnostic methods.

Authors:  Kate Junker; Claire M Buckley; Seán R Millar; Sinéad Flynn; Janas M Harrington; Patricia M Kearney; Ivan J Perry
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

8.  Timing and duration of obesity in relation to diabetes: findings from an ethnically diverse, nationally representative sample.

Authors:  Natalie S The; Andrea S Richardson; Penny Gordon-Larsen
Journal:  Diabetes Care       Date:  2012-12-05       Impact factor: 19.112

9.  Prevalence of diabetes in the Republic of Ireland: results from the National Health Survey (SLAN) 2007.

Authors:  Kevin P Balanda; Claire M Buckley; Steve J Barron; Lorraine E Fahy; Jamie M Madden; Janas M Harrington; Ivan J Perry; Patricia M Kearney
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study.

Authors:  Dominique Simon; Bruno Detournay; Evelyne Eschwege; Stephane Bouée; Jacques Bringer; Claude Attali; Sylvie Dejager
Journal:  Diabetes Ther       Date:  2014-04-12       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.